Supportive care session 1:
|
|
- Angela Paul
- 5 years ago
- Views:
Transcription
1 Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh.
2 Objectives Introduction of CINV Risk factors associated with CINV Categories of CINV Pathophysiology of CINV Therapeutic goal Pharmacologic agents indicated for CINV Current guidelines for CINV management
3 CINV prevalence Occurs in up to 80% of patients receiving CMT 1 In a study of 151 cancer patients from 10 community oncology centers who were scheduled for their first cycle of a new CMT regimen, 67% experienced either acute or delayed CINV during their first CMT cycle. 2 Delayed CINV was more common than acute CINV (59% vs 36%), although many patients experienced both types Anticipatory CINV occurs in 18 57% 3 1. Nevidjon B, Chaudry R. Supportive Oncology. 2010;8: Cohen L et al. Support Care Cancer. 2007;15: National Comprehensive Cancer Network. Antiemesis. Clinical Practice Guidelines in Oncology. 2010;
4 Definitions Nausea Retching Vomiting Anticipatory Breakthrough
5 Patients' Rankings of the Top 5 Chemotherapy Complaints Rank 1983 [1] 1993 [3] 1995 [1] 1999 [4] 2004 [2] 1 Vomiting Nausea Nausea Nausea Fatigue 2 Nausea Constantly Hair loss Hair loss Nausea tired 3 Hair loss Hair loss Vomiting Constantly tired Sleep disturbances 4 Thought of treatment 5 Length of treatment Effect on family Constantly tired Vomiting Vomiting Injections Taste changes Weight loss Hair loss de Boer-Dennert M, et al. Br J Cancer. 1997;76: Abstract Hofman M, et al. Cancer. 2004;101: Abstract Sun CC, et al. Support Care Cancer. 2005;13: Abstract Griffin A, et al. Ann Oncol. 1996;7: Abstract Lindley C, et al. Cancer Practice. 1999;7: Abstract
6 Consequences of CINV Medical complications Electrolyte imbalances Dehydration Quality of life Impact daily functioning Compliance with chemotherapy
7 Risk factors Patient Disease Treatment Age <50 years Women > men History of light alcohol use History of vomiting with prior exposure to CMT Other risks History of motion sickness History of nausea or vomiting during pregnancy History of anxiety GIT Partial/complete bowel obstruction, constipation Gastroparesis Tumor or chemotherapy (eg., vincristine) induced Liver metastases Vestibular dysfunction Increase ICP due to brain metastases Metabolic imbalance Psychophysiologic Anxiety, pain CMT Emetic Risk HIGH (Level 4) >90% MODERATE (Level 3) 31-90% LOW (Level 2) 10-30% MINIMAL (level 1) <10% Hesketh PJ. N Engl J Med 2008;358:
8 CMT Emetogenicity level Emetic Risk Antineoplastic Agents Administered Intravenously High Moderate Low Minimal Carmustine Azacitidine Fluorouracil Panitumumab 2-Chlorodeoxyadenosine Cisplatin Alemtuzumab Bortezomib Pemetrexed Bevacizumab Cyclophosphamide >1500 mg/m 2 Dacarbazine Dactinomycin Mechlorethamine Streptozotocin Bendamustine Carboplatin Clofarabine Cyclophosphamide <1500 mg/m 2 Cytarabine >1000 mg/m 2 Daunorubicin* Doxorubicin* Epirubicin* Idarubicin* Ifosfamide Irinotecan Oxaliplatin Cabazitaxel Catumaxomab Cytarabine <1000 mg/m 2 Docetaxel Doxorubicin HCL liposome injection Etoposide Gemcitabine Ixabepilone Methotrexate Mitomycin Mitoxantrone Paclitaxel Temsirolimus Topotecan Trastuzumab Bleomycin Busulfan Cetuximab Fludarabine Pralatrexate Rituximab Vinblastine Vincristine Vinorelbine *These anthracyclines, when combined with cyclophosphamide, are now designated as high emetic risk Basch E, et al. J Clin Oncol. 2011;29:
9 Categories of CINV Refractory/Intractable Breakthrough Anticipatory Acute Delayed Chemo hours hours Lohr L. J Hematol Oncol Pharm. 2011;1(4):13-21.
10 Pathophysiology Motion Labyrinth disorders Drugs Metabolic products Bacterial toxins ACh H 1 Vestibular System Vestibular nuclei projections Chemoreceptor Trigger Zone Sensory input Anxiety Increased ICP Cortex Intracerebral projections Mechanical stretch GI mucosal injury Local toxins JAMA 2007;298(10): D 2 5HT 3 NK 1 5HT 3 Chemoreceptors Peripheral Pathways Vagus and splanchnic nerves Vomiting Center ACh H 1 5HT 3
11 Neurotransmitter involvements Delayed Acute 5-HT 3 Other factors
12 Neurotransmitter involvements
13 Therapeutic Goal Prevention/ Minimization
14 Pharmacotherapy Aprepitant, March 2003 Palonosetron July, 2003
15 Classes of Antiemetic Agents Serotonin Antagonists Corticosteroids NK 1 Receptor Antagonist (i.e. Aprepitant) Dopamine antagonists Metoclopramide Phenothiazines (i.e. Prochloroperazine) Butyrophenones (i.e. Haloperidol) Benzodiazepines Cannabinoids Olanzapine
16 5HT 3 RA: Practice Pearls Standard therapy for MEC-HEC due to efficacy and low ADRs Addition of corticosteroids is synergistic (20% in effectiveness) Not as effective as corticosteroids for delayed N/V All agents, when administered in equipotent doses, have similar efficacy and safety Palonosetron has longer half-life and more avid receptor binding Granisetron is a patch formulation Current guidelines indicate that PO administration is equivalent to IV administration in efficacy Basch E, et al. J Clin Oncol. 2011;29: Antiemetic Subcommittee of the MASCC. Ann Oncol 2010;21 (Suppl 5):v232-v243. NCCN Guidelines Version Antiemesis. National Comprehensive Cancer Network.
17 5HT 3 RA: Adverse effects Headache Constipation or diarrhea Transient ECG interval abnormalities (QT prolongation), often asymptomatic Somnolence, sedation Elevated transaminases, dizziness
18 5HT 3 RA: FDA Warning!!! September 2011, FDA released an alert concerning an association between Zofran (ondansetron) and prolongation of QT intervals. The FDA required a revision of labeling as follows: to include a warning to avoid use in patients with congenital long QT syndrome.additionally, recommendations for ECG monitoring in patients with electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia), CHF, bradyarrhythmias, or in patients taking other medications that can lead to QT prolongation U.S. Food and Drug Administration. September 15, 2011.
19 5HT 3 RA: FDA Warning!!! A subsequent report the FDA made the following recommendations: A recently completed clinical study suggests that a 32mg single IV dose of ondansetron may affect the electrical activity of the heart (QT interval prolongation), which could predispose patients to develop Torsades de Pointes. Ondansetron will continue to be used in the prevention and treatment of CINV; HOWEVER, no single IV ondansetron dose should exceed 16mg. This does not change any of the recommended oral dosing regimens for ondansetron (max PO dose = 24mg). U.S. Food and Drug Administration. June 29, 2012.
20 Corticosteroids Dosing: Dexamethasone dose ranges from 8-20mg Methylprednisolone dose ranges from mg Reduce dose when used with aprepitant/fosaprepitant Do not give additional steroid if present in treatment regimen Basch E, et al. J Clin Oncol. 2011;29: Antiemetic Subcommittee of the MASCC. Ann Oncol 2010;21 (Suppl 5):v232-v243. NCCN Guidelines Version Antiemesis. National Comprehensive Cancer Network.
21 Corticosteroids: Adverse effects Adverse effects may include: Euphoria, anxiety, insomnia Increased appetite Hyperglycemia Mild fluid retention When IV doses are given too rapidly patient may experience transient and intense perianal, vaginal, or anal burning Basch E, et al. J Clin Oncol. 2011;29: Antiemetic Subcommittee of the MASCC. Ann Oncol 2010;21 (Suppl 5):v232-v243. NCCN Guidelines Version Antiemesis. National Comprehensive Cancer Network.
22 NK 1 RA: Practice Pearls Augments the antiemetic activity of 5-HT 3 RA and corticosteroids to inhibit acute and delayed phases of CINV in both MEC-HEC Do not use as single agent Adverse effects: Fatigue, Hiccups, Weakness, dizziness Basch E, et al. J Clin Oncol. 2011;29: Antiemetic Subcommittee of the MASCC. Ann Oncol 2010;21 (Suppl 5):v232-v243. NCCN Guidelines Version Antiemesis. National Comprehensive Cancer Network.
23 NK 1 RA: Practice Pearls Aprepitant A substrate, a moderate inhibitor An inducer of CYP3A4 when used as a 3-day regimen Fosaprepitant Given as a single dose Weak inhibitor of CYP3A4 (does not induce CYP3A4) Basch E, et al. J Clin Oncol. 2011;29: Antiemetic Subcommittee of the MASCC. Ann Oncol 2010;21 (Suppl 5):v232-v243. NCCN Guidelines Version Antiemesis. National Comprehensive Cancer Network.
24 Merck & Co., Inc. Product Information Chemotherapy induced nausea and vomiting (CINV) NK 1 RA: Drug-Drug interactions Potential drug interactions include: Oral contraceptives (decreased efficacy) Warfarin (decreased efficacy) Dexamethasone/methylprednisolone (increased efficacy) Midazolam (increased efficacy) CYP3A4 inhibitors (increase aprepitant AUC) Erythromycin, itraconazole, ketoconazole, etc CYP3A4 inducers (decrease aprepitant AUC) Carbamazepine, phenytoin, rifampin
25 NK 1 RA: CMT Drug interactions CMT known to be metabolized by CYP3A4: Docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, vincristine Doses were not adjusted when used concurrently with etoposide, vinorelbine, or paclitaxel in phase III trials, but caution is warranted Ifosfamide neurotoxicity Recent study found no association between aprepitant use and the risk of neurotoxicity in patients receiving ifosfamide-based therapy; caution is warranted Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
26 NK 1 RA: Dosage regimens ORAL Aprepitant 125mg PO day 1, 80mg PO days 2 and HT 3 of choice day 1 Dexamethasone 12mg PO day 1, 8mg PO days 2, 3, 4 IV Fosaprepitant 150mg IV day 1 (only) 5-HT 3 of choice day 1 Dexamethasone 12mg PO day 1, 8mg PO day 2, 8mg PO BID days 3 and 4 Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
27 NK 1 RA: Administration Final concentration: 1mg/ml in NSS Infusion > minutes using PVC-free tubing; increase administration time and/or solution volume if phlebitis develops Incompatible with divalent cations (Mg, Ca) infuse through NNS line only Incompatible with palonosetron flush pre/post with NSS Compatible (admix or Y-site) with ondansetron or granisetron and dexamethasone or methylprednisolone May cause hypersensitivity reactions (contains the same base as contained in docetaxel) Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
28 D 2 RA: Phenothiazines Effective with LEC-MEC; delayed N/V Prochlorperazine 10mg PO/IV/IM Q6hr (max of 40mg/day); 25mg Suppo PR Q12hr Promethazine Not a very potent antiemetic for cancer patients IV use mg PO every 4 hours 25mg PO Phenergan ~ = 6.25mg IV Q4-6hr Strong vein irritant; give IV via central line Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
29 D 2 RA: Phenothiazines Adverse effects (class) Sedation (especially with IV and in elderly) Hypotension Akathisia and dystonia Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
30 D 2 RA: Others Metoclopramide D 2 antagonist at lower doses; 5HT 3 RA at high doses Use in breakthrough N/V Dosing: 10-20mg PO/IV Q6hr PRN Most common ADRs diarrhea, dystonia, EPS Haloperidol Used in breakthrough N/V Dosing: 0.5-1mg PO/IV/IM Q6hr PRN Most common ADRs drowsiness, dystonia, dry mouth, EPS Jarkowski,A., et al. The Oncology Pharmacist; April Product Information. Merck & Co.
31 Benzodiazepines Antianxiety agents: Treated ANV or breakthrough CINV They may delay the onset of ANV and help to control sleep disturbances related to diagnosis and chemotherapy Affect the limbic system and cortical input into the medulla Agents commonly recommended: Lorazepam Alprazolam Adverse effects Sedation, dizziness, amnesia, respiratory depression Lohr,L. The Cancer Journal 2008;14(2):85-93.
32 Select Antiemetics for CINV Drug Dose Indication NK 1 RA: Aprepitant/ fosaprepitant 5HT 3 RA: Dolasetron Granisetron Ondansetron Palonosetron ACUTE : 125 mg PO or 115 mg IV DELAYED : 80 mg PO daily x 2 days ACUTE: 100 mg-200 mg PO or 100 mg IV DELAYED: 100 mg PO/IV daily CINV ACUTE: 1 mg-2 mg PO or 1 mg IV or GTDS 3.1 mg/24 hrs DELAYED: 2 mg PO daily or 1 mg PO twice daily (no further dosing with GTDS) ACUTE: 8 mg-24 mg PO or 8 mg-24 mg IV DELAYED: 8 mg PO twice daily or 16 mg PO daily or 8 mg IV twice daily ACUTE: 0.5 mg PO or 0.25 mg IV DELAYED: not recommended (single dose only) Prophylaxis of acute & delayedcinv (with 5HT 3 RA + dexamethasone) Prophylaxis of acute & delayed See above See above See above
33 Select Antiemetics for CINV Drug Dose Indication Benzodiazepines: Alprazolam Lorazepam Corticosteroids: Dexamethasone Dopamine RA: Prochlorperazine Promethazine 0.5 mg-2 mg PO Q 6H 0.5 mg-2 mg PO/IV/Sublingual Q 6H ACUTE : 10 mg-20 mg PO/IV (with aprepitant 12 mg PO/IV) DELAYED: 4 mg-8 mg PO/IV twice daily 10 mg PO/IV Q 6H (may dose Q 4H) 25 mg PR Q 6H 12.5 mg-25 mg PO/IV Q 6H (may dose Q 4H) 25 mg PR Q 6H 6.25 mg/0.1 ml in PLO gel topically Q 4H Anticipatory CINV (drug class of choice) Prophylaxis of acute & delayed CINV (with aprepitant 8 mg PO daily) Treatment of breakthrough CINV; prophylaxis for acute & delayed CINV (with low-risk agents) See above Metoclopramide Droperidol Haloperidol Standard dose: 10 mg-40 mg PO/IV Q 6H (may dose Q 4H) High dose: 0.5 mg/kg-2 mg/kg IV with diphenhydramine 25 mg IV Q 4H mg-1.25 mg IV Q 6H 1 mg IV Q 6H Treatment of breakthrough CINV; prophylaxis of acute (high-dose only) & delayed (with steroids) CINV Treatment of breakthrough CINV See above
34 Practice Guidelines NCCN (National Comprehensive Cancer Network) Revised several times each year Antiemesis pocket Version ASCO (American Society of Clinical Oncology) Updated periodically with most recent in MASCC (Multinational Association of Supportive Care in Cancer) 9 oncology organizations from around the world Most recent update 2011 Other contributors: Oncology Nursing Society (ONS) American Society of Health-System Pharmacists (ASHP)
35 Rule(s) of Thumb Combination therapy: More emetogenic Multiday regimens: At risk for both acute and delayed N/V Emetogenicity is dose-related Emetogenic potential: Different on different days of treatment Antiemetic choices: Based on highest level of emetogenicity
36 Recommendation Professional society ASCO 1 HEC 3-drug combination: NK 1 RA: days HT 3 RA + Dexamethasone: days 1-4 MEC 2-drug combination: Palonosetron + Dexamethasone Preferred If palonosetron is not available, any firstgeneration 5-HT 3 RA, preferably granisetron or ondansetron Evidence on adding aprepitant is limited, but clinicians may consider use of the agent HEC: High-emetic-risk chemotherapy, MEC: Moderate-emetic-risk chemotherapy regimens AC indicates anthracycline plus cyclophosphamide; ASCO, American Society of Clinical Oncology Basch E, et al. J Clin Oncol 2011;29:
37 Recommendation Professional society NCCN 1 HEC Acute and delayed prevention: Prevention: MEC 5-HT 3 RA on day 1 (palonosetron is preferred) + Steroid b on days NK 1 RA on days 1-3 Data for post-cisplatin ( 50 mg/m 2 ) emesis prevention are cat1; others are cat 2A Begin day 1: 5-HT 3 RA (all are cat 1; palonosetron, on day 1 only, is preferred a ) + Steroid b +/- NK 1 RA Days 2 and 3: 5-HT 3 RA (dola, grani,or ondansetron) Or Steroid monotherapy b Or NK 1 RA +/- steroid (if NK 1 antagonist is used on day 1) c HEC: High-emetic-risk chemotherapy, MEC: Moderate-emetic-risk chemotherapy regimens AC indicates anthracycline plus cyclophosphamide, NCCN, National Comprehensive Cancer Network.
38 Recommendation Professional society HEC MASCC/ESMO 1 Acute prevention: 5-HT 3 RA + Dexamethasone, + Aprepitant MEC Acute prevention for AC regimens: 5-HT 3 RA + Dexamethasone + Aprepitant Delayed prevention: Dexamethasone + Aprepitant Delayed prevention (other than AC): Dexamethasone Delayed prevention for AC regimens: Aprepitant HEC: High-emetic-risk chemotherapy, MEC: Moderate-emetic-risk chemotherapy regimens AC indicates anthracycline plus cyclophosphamide; MASCC/ESMO, Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology
39 Conceptual Frame Work: ASCO Regimen: AC Palonosetron: preferred
40 Case Study: Jung Beoi (JB) JB is a 49-year old woman who was recently diagnosed with extensive stage SCLC. She is a non-drinker who stopped smoking 10 years ago. Her PMH is significant for anxiety and motion sickness. Her physician plans to start PE regimen every 28 days to treat her disease. Cisplatin 75mg/m 2 (day 1) Etoposide 100mg/m 2 (days 1-3)
41 Point to consider 1. What is the emetogenic potential of the chemotherapy prescribed for JB? 2. What are the risk factors associated with the development of CINV?
42 Case Study: Jung Beoi JB is a 49-year old woman who was recently diagnosed with extensive stage SCLC. She is a non-drinker who stopped smoking 10 years ago. Her PMH is significant for anxiety and motion sickness. Her physician plans to start PE regimen every 28 days to treat her disease. Cisplatin 75mg/m 2 (day 1) HEC (day 1) Etoposide 100mg/m 2 (days 1-3) LEC (day 1-3)
43 Point to consider 3. What is the rationale for the anti-emetic therapy prescribed in this case? 4. Why are these drugs prescribed in combination?
44 Case Study: Jung Beoi Treatment risk: Cisplatin (day 1) HEC Etoposide (days 1-3) LEC Emetic Pattern: HIGH Risk = 3 days after last dose of CMT MODERATE Risk = 2 days after last dose of CMT LOW Risk = 1 day after last dose of CMT +/- PRN Patient should be protected throughout the full period of risk
45 Case Study: Jung Beoi The FDA recommends a maximum of 16 mg for a single dose of IV ondansetron, PO 24 mg
46 Case Study: Jung Beoi Prophylaxis regimen: 5-HT 3 + NK 1 + corticosteroid* Palonosetron 0.25mg IV day 1 + Dexamethasone 20mg PO/IV day 1, 8mg PO Q12hr day 2-4 Prochlorperazine 10mg PO Q6hr PRN: breakthrough N/V
47 Case Study: Jung Beoi Presents to clinic 5 days after her first cycle of cisplatin and etoposide. She states that she had continuous nausea with several episodes of emesis and is considering no further therapy. She has been using prochlorperazine without significant benefit.
48 Breakthrough: Consideration In case of has no N/V don t change anything In case of has N/V: choose an agent with a different mechanism of action and add PRN to current regimen Take patient-specific characteristics into consideration Anxiety, depression, concurrent medications, dyspepsia Multiple concurrent medications may be required If N/V controlled: continue breakthrough medication(s) on scheduled basis
49 Breakthrough: Consideration If N/V uncontrolled: Consider changing antiemetic therapy to higher-level primary treatment Consider adding aprepitant/fosaprepitant Add other antiemetics, such a dopamine antagonists, butyrophenones Adjust intensity or frequency of 5-HT 3 Changing to a different 5-HT 3 may be of questionable benefit If treatment goal is non-curative, consider different chemotherapy regimen Adding an anxiolytic to combination antiemetics Consider antacid, H 2 antagonist or PPI therapy in patients with dyspepsia
50 Breakthrough: Consideration
51 Breakthrough: JB management Addition of metoclopramide is a very reasonable choice 10-20mg PO Q6hr If she responds favorably, this should be added as a scheduled med to her regimen with the next cycle. If not, consider haloperidol, olanzapine or cannabinoids Others possible: Gabapentin Antihistamine
52 Breakthrough CINV: Olanzapine Inhibit D 2, 5HT, ACh and H 1 receptors Adverse effects: Sedation or sleep disturbance Fatigue, dizziness Dry mouth Weight gain Cautions: Use in elderly Hyperglycemia; an association with onset of DM QT prolongation
53 Olanzapine: Standard prevention Compared with aprepitant-based regimens in MEC-HEC as standard prevention regimen Result: Effective as in acute N/V control More effective in controlling delayed symptoms Dosing: mg/day starting day (HS) before or day of chemotherapy and continue for 5-10 days Navari,RM., et al. J Support Oncol 2011;9:
54 Breakthrough CINV: Olanzapine Chanthawong S, et al. J Clin Oncol 2011;29(suppl; abstract e19596).
55 Breakthrough CINV: Olanzapine Phase II prospective open label (Sep 2009 Jul 2010) Sample: 46 solid tumors patients with HEC Intervention: Olanzapine 5 mg orally every 12 hours (2 doses) in patients experiencing breakthrough emesis Monitoring: evaluated every 6 hours for 24 hours Results: Major respond of 78.2% (CR of 60.8%, PR 17.4%) ADRs: mild including dizziness, fatigue and dyspepsia Chanthawong S, et al. J Clin Oncol 2011;29(suppl; abstract e19596).
56 Refractory CINV Patients with persistent N/V after CMT should be evaluated for other possible causes: Brain metastases Electrolyte abnormalities Tumor infiltration of bowel or other GI abnormalities Other comorbidities
57 Case Study: Jung Beoi 6. What are the options for CINV prophylaxis for JB s next cycle of chemotherapy?
58 Standard prevention: Plan Prophylaxis regimen: 5-HT 3 + NK 1 + corticosteroid* Palonosetron 0.25mg IV day 1 + Aprepitant 120mg PO day 1, 80mg PO day 2,3 + Dexamethasone 12mg PO/IV day 1, 8mg PO day 2-4 Olanzapine 5mg PO Q 12 hr PRN: breakthrough N/V Lorazepam 0.5mg PO hs: Anticipatory N/V
59 Anticipatory CINV: Risk factors Age < 50 years N/V after last CMT administration Feeling warm or hot all over after last CMT administration Susceptibility to motion sickness History of anxiety or depression Experiencing sweating and/or generalized weakness after last CMT administration Aapro, MS., et al. Support Care Cancer 2005;13:
60 Anticipatory CINV: Risk factors
61 Take home messages Evaluate each patient individually Evaluate the emetogenic potential and pattern of the chemotherapeutic regimen to be given Antiemetics are most effective when given prophylactically Flexibility is the key
62 Thank you for your attention!
Guideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More information9/21/2016. Disclosures. Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Introduction. Objectives.
Updates in the Management of Chemotherapy induced Nausea and Vomiting (CINV) Diwura Owolabi, Pharm.D, BCOP Clinical Pharmacy Specialist, Blood and Marrow Transplantation Methodist University Hospital,
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationBy: Dawit Negusu (B.Pharm, MPharm candidate)
Prevalence of Chemo-induced Nausea and Vomiting, and Its impact on Patients Quality of Life at the Oncology Unit of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia By: Dawit Negusu (B.Pharm,
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationReview Article Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 595894, 6 pages http://dx.doi.org/10.1155/2015/595894 Review Article Treatment of Breakthrough and Refractory Chemotherapy-Induced
More informationPREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK
PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN ELDERLY CANCER PATIENTS JØRN HERRSTEDT, M.D. COPENHAGEN UNIVERSITY HOSPITAL HERLEV, DENMARK HISTORY OF ANTIEMETICS 1979 A corticosteroid is superior
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationEssentials. Oncology Practise Essentials. Oncology Basics. Tutorial 5. Toxicity of Chemotherapy Agents
Toxicity of This tutorial reviews the common clinical toxicities of chemotherapy gastrointestinal, dermatological, secondary malignancies, and infertility and their treatment and management. Goals and
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationSue Faulkner, BSN RN OCN October 18, 2017 Updates from Congress 2017
Report: Occurrence and Implications of Chemotherapy-Induced nausea and Vomiting (CINV): Implications for the Oncology Nurse Practitioner to Optimize Patient Outcomes Sue Faulkner, BSN RN OCN October 18,
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationChemotherapy-induced nausea and vomiting (CINV)
At a Glance Practical Implications e54 Author Information e57 Full text and PDF 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple Risk Factors Original Research Claudio Faria, PharmD,
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationAn Old Dog with New Tricks? Olanzapine s Role in Chemotherapy Induced Nausea and Vomiting
An Old Dog with New Tricks? Olanzapine s Role in Chemotherapy Induced Nausea and Vomiting Pharmacotherapy Rounds John Malamakal Pharm.D., M.S. PGY1 Pharmacy Resident South Texas Veterans Health Care System,
More informationCLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS
CLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS Procedure reference: Document owner: 2196 Version: V2.1 Robert Duncombe, The Director
More informationGUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.
Page 1 of 20 Guideline for the management of chemotherapy-induced nausea and vomiting, v2.1.1 GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. Version: 2.1.0 Ratified by: Date
More informationPediatric Trials 23/04/2018. Disclosures. Nausea and Vomiting Control in Adults and Children: Mind the Gap! Learning Objectives
Nausea and Vomiting Control in Adults and Children: Mind the Gap! Disclosures No relevant conflicts of interest Lee Dupuis, RPh, PhD May 5, 2018 2 Learning Objectives At the end of this presentation, attendees
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationStudent Project PRACTICE-BASED RESEARCH
Pharmacist-Driven Management of Chemotherapy Induced Nausea and Vomiting in Hospitalized Adult Oncology Patients. A Retrospective Comparative Study Ramy Elshaboury, PharmD 1 and Kathleen Green, PharmD,
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationEVALUATION OF ADEQUACY OF CONTROL OF CHEMOTHERAPY INDUCED VOMITING IN PAEDIATRIC PATIENTS WITH CANCER AT KENYATTA NATIONAL HOSPITAL
EVALUATION OF ADEQUACY OF CONTROL OF CHEMOTHERAPY INDUCED VOMITING IN PAEDIATRIC PATIENTS WITH CANCER AT KENYATTA NATIONAL HOSPITAL MANGHE ZEPHANIAH KIAMBI (U56/82680/2015) A research dissertation submitted
More informationPublished Ahead of Print on September 26, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on September 26, 2011 as 10.1200/JCO.2010.34.4614 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.34.4614 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2016 NCCN.org Continue Version 1.2016 03/15/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN
More informationDennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; Ross Bindler, PharmD ; and Danial E. Baker, PharmD, FASHP, FASCP
Hosp Pharm 2016;51(2):165 175 2016 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj5102-165 Formulary Drug Reviews Rolapitant Dennis J. Cada, PharmD, FASHP, FASCP (Editor) * ; Ross
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationclinical practice guidelines
clinical practice guidelines Annals of Oncology 21 (Supplement 5): v232 v243, 2010 doi:10.1093/annonc/mdq194 Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN
More informationManagement of chemotherapyinduced nausea and vomiting
p h a r m a c o t h e r a p y Management of induced nausea and vomiting Authors Key words F. Van Ryckeghem and S. Van Belle Antiemetic therapy,, prevention Summary Chemotherapy-induced nausea and vomiting
More informationPing-Tsung Chen, MD; Chuang-Chi Liaw, MD
Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi
More information